These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21119513)

  • 1. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
    Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tissue is the issue: personalized medicine for non-small cell lung cancer.
    Hirsch FR; Wynes MW; Gandara DR; Bunn PA
    Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular predictors of response to chemotherapy in non-small cell lung cancer.
    Andrews J; Yeh P; Pao W; Horn L
    Cancer J; 2011; 17(2):104-13. PubMed ID: 21427554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E; Rosell R
    Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
    Gray J; Simon G; Bepler G
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):545-9. PubMed ID: 17428174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents in advanced non-small-cell lung cancer treatment.
    Ricciardi S; de Marinis F
    Oncology; 2009; 77 Suppl 1():103-12. PubMed ID: 20130438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 measurements in clinical oncology.
    Reed E
    N Engl J Med; 2006 Sep; 355(10):1054-5. PubMed ID: 16957152
    [No Abstract]   [Full Text] [Related]  

  • 10. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of therapy decision-making process for advanced non-small cell lung cancer.
    Gebbia V; Mancuso G; Lombardi L; Maiello E
    Oncology; 2009; 77 Suppl 1():97-102. PubMed ID: 20130437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
    Simon G; Sharma A; Li X; Hazelton T; Walsh F; Williams C; Chiappori A; Haura E; Tanvetyanon T; Antonia S; Cantor A; Bepler G
    J Clin Oncol; 2007 Jul; 25(19):2741-6. PubMed ID: 17602079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
    Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
    Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
    Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
    Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.
    Kim B; Lee HJ; Choi HY; Shin Y; Nam S; Seo G; Son DS; Jo J; Kim J; Lee J; Kim J; Kim K; Lee S
    Cancer Res; 2007 Aug; 67(15):7431-8. PubMed ID: 17671213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer.
    Zalcman G; Bergot E; Creveuil C; Levallet G; Lechapt E
    Curr Opin Oncol; 2011 Jan; 23(1):106-11. PubMed ID: 21076302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 20. The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC).
    Grimminger PP; Schneider PM; Metzger R; Vallböhmer D; Danenberg KD; Danenberg PV; Hölscher AH; Brabender J
    Lung Cancer; 2010 Oct; 70(1):82-7. PubMed ID: 20064672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.